GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lytix Biopharma AS LYTIX.OL · NOK

Health Care · Oslo Børs · 🇳🇴 Norway

Compare

8.38

+6.08%

Close of 9 Nov 2026, in NOK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in NOK, from our data supplier.

FY2025

Revenue

—

FY2017FY2025

Net income

−NOK 60.0m

FY2017FY2025

Free cash flow

−NOK 59.9m

FY2017FY2025

Shareholders' equity

NOK 61.8m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue—NOK 11.1mNOK 4.0mNOK 1.4mNOK 17,000NOK 3,000NOK 310,000NOK 337,000NOK 1.1m
Research and developmentNOK 13.8mNOK 72.6mNOK 63.2mNOK 51.0mNOK 28.8mNOK 16.0mNOK 14.0mNOK 39.9m—
Operating income−NOK 64.0m−NOK 95.9m−NOK 96.8m−NOK 65.7m−NOK 48.0m−NOK 42.4m−NOK 33.8m−NOK 62.4m−NOK 63.8m
Net income−NOK 60.0m−NOK 94.3m−NOK 87.9m−NOK 56.0m−NOK 48.0m−NOK 42.1m−NOK 33.2m−NOK 61.5m−NOK 63.4m
Diluted earnings per share-1.55-2.43-2.27-1.45-1.24-1.09-0.86-1.59-1.64

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsNOK 81.5mNOK 146.5mNOK 63.9mNOK 152.0mNOK 203.0mNOK 32.6mNOK 17.4mNOK 58.9mNOK 47.1m
Cash and short-term investmentsNOK 72.4mNOK 130.8mNOK 50.5mNOK 145.2mNOK 197.3mNOK 28.4mNOK 12.8mNOK 49.6mNOK 35.0m
Total liabilitiesNOK 19.8mNOK 38.6mNOK 12.6mNOK 16.9mNOK 13.3mNOK 12.7mNOK 3.9mNOK 17.9mNOK 35.3m
DebtNOK 1.2mNOK 1.9mNOK 41,000NOK 476,000—————
Shareholders' equityNOK 61.8mNOK 107.9mNOK 51.3mNOK 135.1mNOK 189.6mNOK 19.9mNOK 13.6mNOK 41.0mNOK 11.8m
Shares outstanding39m39m39m39m39m39m39m39m39m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−NOK 59.9m−NOK 70.4m−NOK 96.0m−NOK 52.1m−NOK 44.9m−NOK 24.3m−NOK 36.8m−NOK 72.6m−NOK 69.7m
Capital spending——−NOK 49,000−NOK 154,000−NOK 154,000−NOK 154,000−NOK 154,000——
Free cash flow−NOK 59.9m−NOK 70.4m−NOK 96.0m−NOK 52.3m−NOK 45.1m−NOK 24.5m−NOK 37.0m−NOK 72.6m−NOK 69.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————NOK 377,000NOK 231,000
Operating income−NOK 26.8m−NOK 26.8m−NOK 21.2m−NOK 24.3m−NOK 5.2m−NOK 13.4m−NOK 32.6m−NOK 23.0m
Net income−NOK 26.7m−NOK 25.9m−NOK 18.7m−NOK 23.3m−NOK 5.1m−NOK 12.9m−NOK 31.9m−NOK 22.7m
Diluted earnings per share-0.69-0.67-0.48-0.60-0.13-0.33-0.82-0.59
Cash from operations−NOK 28.0m−NOK 28.0m−NOK 59.0m−NOK 40.0m−NOK 30.0m−NOK 12.0m−NOK 70.0m−NOK 53.0m
Total assetsNOK 100.3mNOK 128.8mNOK 81.5mNOK 95.5mNOK 110.1mNOK 130.1mNOK 146.5mNOK 56.3m
Cash and short-term investments——NOK 72.4mNOK 90.0mNOK 100.3mNOK 117.9mNOK 130.8mNOK 43.5m
Debt——NOK 1.2mNOK 1.5mNOK 1.7mNOK 2.0mNOK 1.9mNOK 2.1m
Shareholders' equityNOK 86.6mNOK 114.5mNOK 61.8mNOK 78.4mNOK 90.0mNOK 95.2mNOK 107.9mNOK 36.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-0.9%8.6%—
Net income2.3%7.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-6.4-2.4-2.1-5.4-11.1
Price to sales—20.547.2213.3—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.